Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH GIRA

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1861481152
CMS profile
39241
Location
DES PERES, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$18,463.29

173 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Long term medical supply or device loan $7,474.85 1
Food and Beverage $7,211.37 166
Consulting Fee $2,650.00 2
Travel and Lodging $1,002.77 3
Entertainment $124.30 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH GIRA

NPI 1861481152 · CMS profile ID 39241

Allopathic & Osteopathic Physicians / Ophthalmology

DES PERES, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861481152?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH GIRA, NPI 1861481152, CMS profile ID 39241. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861481152?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOSEPH GIRA, NPI 1861481152, CMS profile ID 39241. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861481152?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOSEPH GIRA, NPI 1861481152, CMS profile ID 39241, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1861481152?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

173 matching records · $18,463.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 173 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 173.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ocular Therapeutix, Inc. $36.1910/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148200107 CMS
Tarsus Pharmaceuticals, Inc. $32.5210/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139098901 CMS
Bausch & Lomb Americas Inc. $15.2609/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140376273 CMS
Sight Sciences, Inc. $142.1709/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151927477 CMS
Bausch & Lomb Americas Inc. $24.6609/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140376271 CMS
Johnson & Johnson Surgical Vision, Inc. $145.4209/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077598836 CMS
Johnson & Johnson Surgical Vision, Inc. $39.1309/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077598840 CMS
Glaukos Corporation $33.2309/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151989358 CMS
Alcon Vision LLC $15.2509/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110607174 CMS
Sight Sciences, Inc. $14.2808/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151927469 CMS
ABBVIE INC. $7.0108/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103801246 CMS
Sight Sciences, Inc. $10.1308/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151932693 CMS
Alcon Vision LLC $120.8108/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110605334 CMS
Carl Zeiss Meditec USA, Inc. $82.2008/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153261928 CMS
Harrow Eye, LLC $24.8508/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145603682 CMS
Sight Sciences, Inc. $2.3808/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151932673 CMS
Glaukos Corporation $28.4208/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151989356 CMS
Johnson & Johnson Surgical Vision, Inc. $39.5607/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077598838 CMS
Alcon Vision LLC $13.9207/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110607168 CMS
RxSight Inc $25.0007/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144217152 CMS
Alcon Vision LLC $27.8807/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110605316 CMS
ABBVIE INC. $5.9107/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103801244 CMS
Alcon Vision LLC $54.0107/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110605328 CMS
Dompe US, Inc. $124.9907/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151407247 CMS
Tarsus Pharmaceuticals, Inc. $29.9007/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139098899 CMS
Bausch & Lomb Americas Inc. $20.1007/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140376287 CMS
Sight Sciences, Inc. $20.8307/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151927471 CMS
Johnson & Johnson Surgical Vision, Inc. $18.4107/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077598816 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $15.0807/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152164128 CMS
Tarsus Pharmaceuticals, Inc. $23.6107/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139098897 CMS
Harrow Eye, LLC $24.3807/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145603680 CMS
ABBVIE INC. $13.0007/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103801242 CMS
Alcon Vision LLC $33.2207/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110605320 CMS
Johnson & Johnson Surgical Vision, Inc. $5.0306/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077598822 CMS
Sight Sciences, Inc. $2.8606/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151932677 CMS
Alcon Vision LLC $20.7506/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110605308 CMS
Sight Sciences, Inc. $10.8006/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151932695 CMS
Johnson & Johnson Surgical Vision, Inc. $19.8106/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077598832 CMS
Tarsus Pharmaceuticals, Inc. $32.1706/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139098895 CMS
Alcon Vision LLC $47.6006/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110605324 CMS
Sight Sciences, Inc. $13.8106/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151927467 CMS
ABBVIE INC. $19.5306/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103801238 CMS
ABBVIE INC. $11.1806/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103801240 CMS
Bausch & Lomb Americas Inc. $21.0405/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140376269 CMS
Alcon Vision LLC $101.0105/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110605332 CMS
Sight Sciences, Inc. $11.4505/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151932701 CMS
Alcon Vision LLC $139.0705/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110598862 CMS
Amgen Inc. $23.3105/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111584210 CMS
Alcon Vision LLC $15.3805/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110607176 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $129.9105/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152164126 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $31,019.28 205
PY2020 $6,963.47 133
PY2021 $21,002.83 204
PY2022 $61,016.82 209
PY2023 $12,652.21 139
PY2024 $18,463.29 173
PY2025 $23,237.04 199

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $26,147.08 36
PY2024 Principal investigator $78,272.07 38
PY2023 Recipient $130,778.75 5
PY2023 Principal investigator $54,087.50 41
PY2022 Recipient $77,575.75 3
PY2022 Principal investigator $113,247.20 20
PY2021 Recipient $73,344.00 9
PY2021 Principal investigator $171,891.92 39
PY2020 Recipient $29,284.33 10
PY2020 Principal investigator $97,700.82 30
PY2019 Recipient $94,177.20 13
PY2019 Principal investigator $210,277.40 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Glaukos Corporation $320.00 12/10/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250907064
Principal investigator 1 Glaukos Corporation $550.00 11/19/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250907059
Principal investigator 1 Glaukos Corporation $1,500.00 10/08/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250907073
Principal investigator 1 Glaukos Corporation $640.00 09/10/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250907055
Principal investigator 1 Glaukos Corporation $394.74 08/27/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903878
Principal investigator 1 Glaukos Corporation $14.52 08/13/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250902499
Principal investigator 1 Glaukos Corporation $59.12 08/13/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250902673
Principal investigator 1 Glaukos Corporation $394.74 07/23/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903734
Principal investigator 1 Glaukos Corporation $4.71 07/09/2025 Non-covered Recipient Entity
Amazon.com, Inc.
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250908938
Principal investigator 1 Glaukos Corporation $870.00 07/02/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250907051
Principal investigator 1 Glaukos Corporation $17.72 06/18/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903045
Principal investigator 1 Glaukos Corporation $15.88 06/11/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903111
Principal investigator 1 Glaukos Corporation $517.24 06/04/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250903991
Principal investigator 1 Glaukos Corporation $1,100.00 06/04/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250907047
Principal investigator 1 Glaukos Corporation $197.37 05/29/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250904115
Principal investigator 1 Glaukos Corporation $197.37 05/29/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250904258
Principal investigator 1 Glaukos Corporation $114.84 05/14/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903295
Principal investigator 1 Glaukos Corporation $394.74 05/14/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250904678
Principal investigator 1 Glaukos Corporation $1,025.00 05/07/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250907043
Principal investigator 1 Glaukos Corporation $517.24 04/02/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904543
Principal investigator 1 Glaukos Corporation $2,135.00 04/02/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250906805
Principal investigator 1 Glaukos Corporation $1,880.00 04/02/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250907039
Principal investigator 1 Glaukos Corporation $285.00 04/02/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250907070
Principal investigator 1 Glaukos Corporation $2.66 03/19/2025 Non-covered Recipient Entity
Amazon.com, Inc.
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250909325
Principal investigator 1 Glaukos Corporation $258.62 03/12/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250905032
Principal investigator 1 Glaukos Corporation $1,690.00 03/05/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250906800
Principal investigator 1 Glaukos Corporation $1,920.00 03/05/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250907032
Principal investigator 1 Glaukos Corporation $4.67 03/05/2025 Non-covered Recipient Entity
Amazon.com, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250909541
Principal investigator 1 Glaukos Corporation $394.74 02/26/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250905072
Principal investigator 1 Glaukos Corporation $258.62 02/19/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904921
Principal investigator 1 Glaukos Corporation $421.30 02/19/2025 Non-covered Recipient Entity
Commercial Print Management
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250907876
Principal investigator 1 Glaukos Corporation $258.62 01/29/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904806
Principal investigator 1 Glaukos Corporation $154.00 01/29/2025 Non-covered Recipient Entity
InComm Digital Solutions, LLC
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250907215
Principal investigator 1 Glaukos Corporation $258.62 01/08/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250905492
Principal investigator 1 Glaukos Corporation $5,915.00 01/08/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus No dispute reported 06/30/2026 1250906796
Principal investigator 1 Glaukos Corporation $1,465.00 01/08/2025 Non-covered Recipient Entity
Ophthalmology Consultants, Ltd
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250907028